2025
Cerebral perfusion differences in the visual cortex and fusiform subregions across the psychosis spectrum
Sritharan J, Zeng V, Petr J, Mutsaerts H, Hoang D, Bolo N, Ivleva E, Dai W, Gershon E, Keedy S, Parker D, Trotti R, McDowell J, Clementz B, Tamminga C, Pearlson G, Keshavan M, Lizano P. Cerebral perfusion differences in the visual cortex and fusiform subregions across the psychosis spectrum. Frontiers In Psychiatry 2025, 16: 1566184. PMID: 40365009, PMCID: PMC12069394, DOI: 10.3389/fpsyt.2025.1566184.Peer-Reviewed Original ResearchPsychosis spectrum disordersFusiform gyrusSchizoaffective disorderPseudo-continuous arterial spin-labeling scansCerebral blood flowOccipital lobeOverall cognitive performanceArterial spin labeling scansGray matter cerebral blood flowPsychosis spectrumBipolar disorderCognitive measuresCognitive performancePsychosisSpectrum disorderDiagnostic groupsPerfusion differencesVisual processingCognitive impairmentVisual hallucinationsCytoarchitectonic subregionsPerfusion alterationsLabeling scansSchizophreniaHealthy controls
2023
Cognitive impairment in long-COVID and its association with persistent dysregulation in inflammatory markers
Damiano R, de Almeida Rocca C, de Pádua Serafim A, Loftis J, Talib L, Pan P, Cunha-Neto E, Kalil J, de Castro G, Seelaender M, Guedes B, Marie S, de Souza H, Nitrini R, Miguel E, Busatto G, Forlenza O, Group H, Utiyama E, Segurado A, Perondi B, Miethke-Morais A, Montal A, Harima L, Fusco S, Silva M, Rocha M, Marcilio I, Rios I, Kawano F, de Jesus M, Kallas É, Carmo C, Tanaka C, Marchini J, Carvalho C, Ferreira J, Levin A, Oliveira M, Guimarães T, dos Santos Lázari C, da Silva Duarte A, Sabino E, Magri M, Barros-Filho T, Francisco M. Cognitive impairment in long-COVID and its association with persistent dysregulation in inflammatory markers. Frontiers In Immunology 2023, 14: 1174020. PMID: 37287969, PMCID: PMC10242059, DOI: 10.3389/fimmu.2023.1174020.Peer-Reviewed Original ResearchConceptsCognitive impairmentInflammatory markersSARS-CoV-2 infectionLong-term cognitive impairmentLong-term cognitive outcomesC-reactive proteinDisease severity markersCOVID-19 infectionCognitive performanceHospital dischargeInflammatory backgroundClinical statusD-dimerSeverity markersGeneral cognitionOverall cognitive performanceTNF-betaPhysical activityParticipants 6Severe formG-CSFPersistent dysregulationMultivariate analysisSociodemographic characteristicsCognitive deficits
2021
The microRNA-195 - BDNF pathway and cognitive deficits in schizophrenia patients with minimal antipsychotic medication exposure
Pan S, Feng W, Li Y, Huang J, Chen S, Cui Y, Tian B, Tan S, Wang Z, Yao S, Chiappelli J, Kochunov P, Chen S, Yang F, Li CR, Tian L, Tan Y, Elliot Hong L. The microRNA-195 - BDNF pathway and cognitive deficits in schizophrenia patients with minimal antipsychotic medication exposure. Translational Psychiatry 2021, 11: 117. PMID: 33558459, PMCID: PMC7870897, DOI: 10.1038/s41398-021-01240-x.Peer-Reviewed Original ResearchConceptsBDNF protein levelsBrain-derived neurotrophic factorAntipsychotic medication exposureBDNF protein expressionMATRICS Consensus Cognitive BatteryMiR-195Medication exposureBDNF mRNABDNF proteinCognitive functionProtein levelsCognitive impairmentLower BDNF protein levelsCognitive deficitsSex-matched healthy controlsProtein expressionSubgroup of patientsFirst-episode patientsMiR-195 expressionBDNF reductionMedication-naïveNeurotrophic factorPeripheral bloodHealthy controlsOverall cognitive performance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply